Genotyping News and Research

RSS

Roche releases new software for accurate sequencing of long 16S ribosomal RNA amplicons

Roche announced today the global launch of a new software update that significantly extends the range of amplicon lengths available for targeted next-generation sequencing studies on the 454 GS FLX+ System.

7 Aug 2013

Verinata Health receives New York's Laboratory Permit for CLIA-certified verifi prenatal test

Illumina, Inc. (NASDAQ: ILMN) today announced that Verinata Health, an Illumina company, received the Clinical Laboratory Permit from the New York State Department of Health for its CLIA-certified, CAP-accredited laboratory.

2 Aug 2013

Affymetrix introduces cost-effective, high-throughput Axiom 384HT format for genotyping

Affymetrix, Inc. (NASDAQ: AFFX) announces the introduction of the Axiom® 384HT genotyping format, a breakthrough cost-effective, high-throughput format for genotyping in which 384 samples are simultaneously processed with 384 discrete microarrays in a microplate format analyzing up to 50,000 SNPs per sample.

30 Jul 2013

HistoGenetics selects MiSeq sequencing system from Illumina for use in CLIA laboratory

Illumina, Inc. today announced that HistoGenetics, the leader in high-resolution sequence-based human leukocyte antigen testing services, has selected the MiSeq sequencing system for use in its CLIA laboratory.

From Illumina, Inc. 22 Jul 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Bioline announces worldwide release of MyTaq Extract-PCR Kit

Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc., is proud to announce the worldwide release of the MyTaq Extract-PCR Kit.

2 Jul 2013

UH and Case Western Reserve University to develop diagnostic tests to determine HIV drug resistance

Case Western Reserve University has signed an exclusive worldwide licensing agreement granting University Hospitals Case Medical Center rights to a series of diagnostic tests to determine drug resistance and co-receptor tropism in human immunodeficiency virus.

2 Jul 2013

Teva signs agreement with Verinata Health for commercialization of verifi prenatal test in Israel

Illumina, Inc. today announced that Teva Pharmaceutical Industries Ltd. signed an exclusive agreement with Verinata Health, an Illumina company, for the commercialization of the verifi non-invasive prenatal test in Israel.

1 Jul 2013

RUCDR Infinite Biologics receives $44.5 million Cooperative Agreement award from NIMH centre

RUCDR Infinite Biologics, the world's largest university-based biorepository, received a $44.5 million Cooperative Agreement award from the National Institute of Mental Health earlier this month to support its NIMH Center for Collaborative Genomics Research on Mental Disorders, which provides services to NIMH-funded scientists engaged in genomic research on mental disorders.

28 Jun 2013

Abbott RealTime HCV Genotype II assay receives FDA approval

The U.S. Food and Drug Administration today approved a test that identifies the genotype of hepatitis C virus that a patient is carrying. The Abbott RealTime HCV Genotype II, which can differentiate genotypes 1, 1a, 1b, 2, 3, 4, and 5,using a sample of an infected patient's blood plasma or serum, will aid health care professionals in determining the appropriate approach to treatment.

21 Jun 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

13 Jun 2013

Prostate cancer and DNA: an interview with Dr. Jianfeng Xu, Wake Forest School of Medicine

Prostate cancer development is associated with both inherited and acquired genetic alterations. More than 70 inherited genetic variants have been consistently identified in human DNA that may contribute to susceptibility or risk of prostate cancer.

11 Jun 2013

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

New findings presented today during the APASL Liver Week in Singapore, highlighted the efficacy and safety of faldaprevir+ plus pegylated interferon and ribavirin (PegIFN/RBV) in treatment-naïve patients with genotype-1 hepatitis C virus (HCV) in Asia.1 This post-hoc sub-analysis of the Phase III STARTVerso™1 and 2 trials showed that both doses of faldaprevir were associated with high viral cure rates and a shorter treatment duration in this particular patient group.1

10 Jun 2013

Study: New genetic marker predicts warfarin dose in African-Americans

A newfound genetic marker promises to better predict warfarin dose in African-Americans, according to a study published online today in The Lancet. If confirmed in further studies, the finding may help to avert more of the bleeds and blood clots that come when a patient's starting dose misses the drug's narrow safety window.

5 Jun 2013

RUCDR Infinite Biologics creates new Genomics Technology Center

RUCDR Infinite Biologics, the world's largest university-based biorepository, has completed an $11.8 million renovation project to create a new Genomics Technology Center, comprising 12,500 square feet of laboratory, office, and storage space on the Busch Campus of Rutgers, The State University of New Jersey.

18 May 2013

Illumina releases genomics cloud computing and storage platform

Illumina, Inc. today announced the full commercial availability of BaseSpace, the Company's genomics cloud computing and storage platform.

From Illumina, Inc. 16 May 2013

Good Start Genetics gets $28M loan from Capital Royalty

Good Start Genetics, Inc., an innovative molecular diagnostics company that has developed the new gold standard in carrier screening, today announced that it has closed a non-dilutive loan facility for up to $28 million of capital from Capital Royalty L.P.

8 May 2013

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Vertex Pharmaceuticals Incorporated today announced data from a Phase 2 study of VX-661 and ivacaftor that showed statistically significant improvements in lung function among adults with cystic fibrosis (CF) who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, known as F508del.

22 Apr 2013

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Researchers have newly associated nine genetic regions with a rare autoimmune disease of the liver known as primary sclerosing cholangitis (PSC). This brings the total number of genetic regions associated with the disease to 16.